Sanofi ROE 2006-2018 | SNY

Current and historical return on equity (ROE) values for Sanofi (SNY) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Sanofi ROE for the three months ending June 30, 2018 was 17.64%.
Sanofi ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2018-06-30 $3.57B $67.22B 10.72%
2018-03-31 $4.71B $0.00B 14.55%
2017-12-31 $9.53B $65.85B 29.46%
2017-09-30 $9.90B $0.00B 31.05%
2017-06-30 $9.92B $63.58B 31.13%
2017-03-31 $10.09B $0.00B 32.21%
2016-12-31 $5.21B $63.88B 16.64%
2016-09-30 $6.19B $0.00B 40.31%
2016-06-30 $5.76B $61.39B 18.55%
2016-03-31 $5.52B $0.00B 16.49%
2015-09-30 $4.90B $0.00B 9.45%
2015-06-30 $4.59B $62.80B 6.57%
2014-06-30 $5.57B $71.01B 10.27%
2013-06-30 $6.39B $73.39B 11.39%
2012-06-30 $8.61B $72.42B 22.81%
2012-03-31 $8.56B $0.00B 22.19%
2011-12-31 $9.33B $78.54B 24.20%
2011-09-30 $8.04B $0.00B 21.95%
2011-06-30 $7.45B $75.69B 20.36%
2011-03-31 $8.22B $0.00B 23.85%
2010-12-31 $8.24B $70.76B 23.90%
2010-09-30 $9.30B $0.00B 27.63%
2010-06-30 $10.37B $67.09B 30.81%
2010-03-31 $11.38B $0.00B 35.40%
2009-12-31 $10.99B $67.56B 34.20%
2009-09-30 $9.57B $0.00B 30.08%
2009-06-30 $8.26B $61.00B 25.94%
2009-03-31 $7.76B $0.00B 23.66%
2008-12-31 $7.76B $66.31B 23.68%
2008-09-30 $9.72B $0.00B 30.82%
2008-06-30 $10.42B $64.83B 33.04%
2008-03-31 $9.21B $0.00B 29.84%
2007-12-31 $8.40B $61.30B 27.21%
2007-09-30 $6.95B $0.00B 23.22%
2007-06-30 $6.45B $62.17B 21.56%
2007-03-31 $7.18B $0.00B 25.15%
2006-12-31 $6.99B $57.56B 24.47%
2006-09-30 $6.79B $0.00B 23.61%
2006-06-30 $6.95B $56.70B 24.18%
2006-03-31 $6.66B $0.00B 23.26%
2005-12-31 $5.54B $58.32B 19.34%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $103.057B $40.701B
Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing of healthcare products. Its strategy is built around three priorities to reach its goals and ensure sustainable growth. The priorities are: increasing innovation in Research and Development, adapting Group structures to future challenges and seizing external growth opportunities. Sanofi-Aventis specializes in six therapeutic areas: thrombosis, cardiovascular, metabolic disorders, oncology, central nervous system (CNS) and internal medicine. The Company offers vaccines in five areas: pediatric combination vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines. Sanofi-Aventis is headquartered in Paris, France.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $371.636B 16.85
Pfizer (PFE) United States $237.400B 13.29
Merck (MRK) United States $199.302B 17.03
Novartis AG (NVS) Switzerland $178.563B 15.19
Eli Lilly (LLY) United States $120.673B 20.95
Novo Nordisk (NVO) Denmark $118.536B 19.17
AbbVie (ABBV) United States $115.027B 9.86
GlaxoSmithKline (GSK) United Kingdom $99.174B 13.02
AstraZeneca (AZN) United Kingdom $98.200B 11.20
Bristol-Myers Squibb (BMY) United States $74.835B 11.51